Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting
Electra Therapeutics Presents SURPASS Pivotal ELA026 Study Design and Highlights the Critical Unmet Need in Secondary Hemophagocytic Lymphohistiocytosis (sHLH) at the ASH 2025 Annual Meeting GlobeNewswire December 02, 2025 SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) — Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology […]